Markets:

Overview

News

Currencies

International

Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

261.25 +1.28 (+0.49%)

Streaming Delayed Price Updated: 3:11 PM EDT, Jun 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

August 18, 2025

From Natera, Inc.

Via Business Wire

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

August 12, 2025

Via Benzinga

NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures

August 12, 2025

Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue...

Via StockStory

Topics Artificial Intelligence

2 Mid-Cap Stocks on Our Watchlist and 1 We Brush Off

August 12, 2025

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

5 Analysts Have This To Say About Natera ↗

August 11, 2025

Via Benzinga

How Is The Market Feeling About Natera? ↗

August 08, 2025

Via Benzinga

1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Turn Down

August 11, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

Tech Stocks Eye Record Highs As Magnificent Seven Top $19.5 Trillion: What's Moving Markets Friday? ↗

August 08, 2025

Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and...

Via Benzinga

Why Are Natera (NTRA) Shares Soaring Today

August 08, 2025

Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 11.6% in the morning session after it reported strong second-quarter 2025 financial results, including a significant revenue beat and...

Via StockStory

Topics Earnings World Trade

SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday ↗

August 08, 2025

Via Benzinga

Topics Artificial Intelligence

Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6%

August 08, 2025

Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue...

Via StockStory

Natera NTRA Q2 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

Natera (NTRA) Q2 Revenue Jumps 32% ↗

August 07, 2025

Via The Motley Fool

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

How Do Investors Really Feel About Natera? ↗

August 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 07, 2025

Via Benzinga

Natera Reports Second Quarter 2025 Financial Results

August 07, 2025

From Natera, Inc.

Via Business Wire

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

August 07, 2025

From Natera, Inc.

Via Business Wire

What To Expect From Natera’s (NTRA) Q2 Earnings

August 05, 2025

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

August 01, 2025

From Natera, Inc.

Via Business Wire

Natera to Report Its Second Quarter Results on August 7, 2025

July 31, 2025

From Natera, Inc.

Via Business Wire

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

July 29, 2025

From Natera, Inc.

Via Business Wire

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today ↗

July 28, 2025

Via Benzinga

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

July 24, 2025

From Natera, Inc.

Via Business Wire

Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗

July 20, 2025

Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance, and analyst downgrades.

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

July 15, 2025

Via Benzinga

1 Unprofitable Stock for Long-Term Investors and 2 to Approach with Caution

July 08, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

July 07, 2025

From Natera, Inc.

Via Business Wire

1 Growth Stock with Exciting Potential and 2 to Be Wary Of

July 03, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

July 01, 2025

From Natera, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.